Pulmatrix, Inc. (PULM)
NASDAQ: PULM · IEX Real-Time Price · USD
2.020
+0.070 (3.59%)
Jul 22, 2024, 9:30 AM EDT - Market open
Pulmatrix Employees
Pulmatrix had 22 employees as of December 31, 2023. The number of employees decreased by 7 or -24.14% compared to the previous year.
Employees
22
Change (1Y)
-7
Growth (1Y)
-24.14%
Revenue / Employee
$531,091
Profits / Employee
-$402,182
Market Cap
7.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
XWELL | 337 |
Telesis Bio | 147 |
Mainz Biomed B.V. | 71 |
NeuroMetrix | 26 |
Notable Labs | 16 |
Innovative Eyewear | 11 |
Shuttle Pharmaceuticals Holdings | 8 |
Virios Therapeutics | 4 |
PULM News
- 7 weeks ago - Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PRNewsWire
- 2 months ago - Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - PRNewsWire
- 2 months ago - Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 7 months ago - Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives - PRNewsWire
- 9 months ago - Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 10 months ago - Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine - PRNewsWire
- 11 months ago - Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole - PRNewsWire